Real questions from real people exploring psychedelics because, while I’m not a doctor or scientist, “Ask April” is how meaningful dialogue begins.
Below is the full Q&A from the Psychedelic Salon Psychedelics & Seniors recorded live with three featured speakers: Abbie Rosner, author of Psychedelics and the Counterculture of Aging, published in July and based on interviews with 36 older adults, who also writes ELDEREVOLUTION on Substack; Scott Wright, filmmaker and director of The Next Chapter, who took his own first psychedelic journey at 68, three years before this Salon, at a retreat in San Miguel de Allende, Mexico; and Dr. Emily Whinkin, naturopathic physician and integrative mental health specialist licensed in both Oregon and Washington, who hosts a monthly virtual integration circle built specifically for older adults.
If you enjoyed this week’s podcast episode featuring a live recording of the Psychedelic Salon featuring these guests, plan to join me, Scott, and Abbie on Sunday, September 13th @4-6pmPT for a live virtual screening followed by a panel discussion. You can learn more and get tickets here.
Why cardiac conditions, not just psychiatric ones, require individual evaluation before using psychedelic medicine
What the current evidence actually says about SSRIs and psilocybin interactions, including where the science is still unsettled
Which psychiatric diagnoses represent hard contraindications for psychedelic medicine and which require more nuanced clinical assessment
Whether microdosing is safe for people who are highly sensitive to psychoactive substances, including protocol and potency guidance
How psilocybin disrupts entrenched cognitive patterns in older adults and what the default mode network has to do with it
How intergenerational trauma and childhood sexual abuse surface in psychedelic sessions for older adults
What a legal psilocybin session in Oregon costs, what that price includes, and how to access sliding scale options
Why a session that doesn’t produce a visible shift is not the same as a session that didn’t work
What the early neuroinflammation and telomere research suggests about psilocybin and cognitive aging
How ketamine and psilocybin differ pharmacologically and legally, and how to think about choosing between them
Why integration circles matter as real infrastructure against isolation, backed by verified Surgeon General data on dementia risk and Medicare spending
Yes, and this came up in multiple forms throughout the Q&A: atrial fibrillation, valvular conditions, vasculitis, and blood pressure concerns. Dr. Whinkin’s position is consistent with broader clinical practice in psychedelic medicine. Any cardiac history warrants a conversation with a cardiologist before proceeding. Blood pressure stability, clot history, and whether conditions are actively managed all factor into the risk assessment.
The Spirit Pharmacist was named as a specific resource: a doctor of pharmacy who consults on interactions between psychedelic medicine, medical history, and medications. People whose primary care providers are not familiar with psychedelics, or who are not comfortable asking their doctor directly, may want to seek specialized consultation.
The key clinical principle that runs through all of this is that contraindications are evaluated individually. A history of cardiac vasculitis does not automatically disqualify someone. Rather, it changes the dosing conversation because lower doses, monitored closely, may be appropriate where full-dose psilocybin is not.
This is one of the most common practical questions in the psychedelic medicine space, and the evidence is genuinely mixed. SSRIs (selective serotonin reuptake inhibitors) and psilocybin act on overlapping serotonin pathways. Earlier studies suggested SSRIs blunt the psilocybin experience by occupying the receptors psilocybin needs to bind to. More recent evidence suggests the combination may be safer than previously thought, though the experiential blunting effect still appears to hold.
The practical implication: people on SSRIs often report needing a higher dose to achieve a comparable experience. What “higher dose” means for any individual depends on the specific SSRI, how long they have been on it, and other clinical factors. SNRIs (selective norepinephrine reuptake inhibitors) introduce a different set of pharmacological considerations.
This is not a question to navigate without qualified support. It is also not, per the panel, an automatic disqualifier. It is a variable problem, and it requires someone with current clinical knowledge to help assess it.
Three conditions came up as consistent hard stops across the panel: a personal diagnosis of schizophrenia, bipolar disorder with psychosis, and first-degree family history of either. Psychedelics, including psilocybin, can trigger psychotic episodes in people with these vulnerabilities, and that risk holds whether or not they have previously used psychedelics without incident.
Abbie Rosner added a complication worth noting: some people with a bipolar diagnosis who have been stable for an extended period, and who are not in a phase where medication changes are needed, have used psychedelics with reported benefit. The operative word is “some,” and the standard the panel set is individualized care with a guide who understands the diagnosis and has planned for contingencies. That is not the same as saying bipolar disorder is no longer a concern. It means the conversation is more nuanced than a blanket prohibition, and it requires a clinician who can hold that nuance.
Cannabis carries the same psychosis risk profile for people with these vulnerabilities, which is relevant given how often cannabis and psychedelics appear in the same wellness conversation.
Johns Hopkins has been working to enroll participants for an Alzheimer’s trial. Dr. Whinkin noted that, as of the Salon, enrollment had been difficult to complete. The focus of that trial is the depression that frequently accompanies an Alzheimer’s diagnosis, not stopping disease progression.
The more active area of current research is neuroinflammation. Psychedelics appear to have anti-inflammatory effects in the brain, which has implications for conditions driven by neuroinflammatory processes, including neurodegenerative diseases. Whether those effects translate to slowing the progression of conditions like Alzheimer’s is a research question, not an established finding.
The telomere finding Dr. Whinkin mentioned is early and worth flagging carefully: animal and preliminary studies suggest psilocybin may reduce the rate of telomere shortening, which is associated with cellular aging. This does not mean psilocybin extends lifespan. It means a specific mechanism involved in aging may be modulated by the compound. Human clinical data on this is not yet robust.
Abbie Rosner’s framing was direct and well-grounded: the primary benefit she observed in interviews with older adults was a disruption of entrenched cognitive patterns. Decades of life produce deeply grooved ways of thinking, self-narratives that have been reinforced so many times they feel like identity rather than habit. Psilocybin, through its effects on the default mode network, can loosen that grip and introduce what she called a freshness of perspective.
The default mode network is the brain system involved in self-referential thinking, rumination, and the narrative self. Classic psychedelics like psilocybin quiet DMN activity, which is associated with reduced rigidity, increased openness to new perspectives, and the ability to observe one’s own thought patterns from a different vantage point. In older adults who have spent a lifetime reinforcing particular ways of seeing themselves and the world, that shift can feel significant.
Grief is a related thread. Multiple panelists addressed the question of whether psilocybin produces resolution, and the answer was no, not reliably, not permanently, not necessarily in a single session. What it can do is crack open grief that has been held or suppressed for years and allow it to move. Processing grief is not the same as finishing it, and a common report is tears of grief during a session, tears of joy afterward.
Abbie Rosner’s research found this specific pattern with striking consistency: encounters with ancestors surfacing repeatedly in older adults’ sessions, often tied directly to trauma. She described one woman’s ayahuasca journey in which a visual encounter with a long line of ancestors, all connected to abuse she had survived, allowed her to sever that line. The woman later described the work as done for the people behind her and those ahead of her.
On sexual trauma specifically: a disheartening number of the older women Abbie interviewed had histories of sexual abuse and were actively working through it in medicine journeys, some to significant effect. Scott Wright’s documentary The Next Chapter includes a woman who survived childhood sexual abuse by a family member, spent decades in suicidal depression, and describes psilocybin therapy as having set her free. He has described the footage as some of the most moving material in the film.
None of this happened in a single session for the people involved. The pattern across these accounts is repeated, sustained work rather than a single breakthrough, and the researchers involved are careful not to present it otherwise.
The neuroinflammatory evidence is the strongest current basis for claims of cognitive benefit. Psilocybin appears to reduce neuroinflammation, support blood-brain barrier function, and improve the quality of sleep-based brain detox processes. These are relevant to cognitive health broadly, not specific to psychedelic medicine for older adults.
The telomere data, again, is preliminary. The study Dr. Whinkin referenced found that psilocybin may reduce the rate of telomere degradation, not reverse it. The relevance to longevity is speculative at this stage.
On the risk side: psilocybin is federally a Schedule I substance. Using it outside a licensed clinical setting, which for most people in most states is still the only available option, carries legal risk. The substance itself carries medical risk for people with the contraindications listed above. Neither of these facts negates the evidence base, but both are part of an honest accounting.
Duration is the primary practical difference. An LSD session runs approximately nine to eleven hours. A psilocybin session typically runs four to six hours. For older adults managing physical stamina, the shorter psilocybin window is often clinically preferable.
The research on LSD is producing its own emerging findings. Dr. Whinkin highlighted a trial by MindMed on an LSD analog (MM-120) specifically for generalized anxiety disorder, with early results showing significant reductions on validated anxiety symptom measures. Treatment-resistant anxiety has not received the same research attention as treatment-resistant depression, but it is extremely common in clinical practice and difficult to treat with existing tools.
Contraindications for LSD largely parallel those for psilocybin. The same psychiatric exclusions apply as do similar cardiac cautions.
This question comes up often from people who have legal access to both, since ketamine-assisted therapy is legal and clinically established while psilocybin remains restricted outside Oregon’s regulated program or decriminalized jurisdictions.
The two are pharmacologically distinct. Ketamine is a synthetic dissociative anesthetic, first FDA-approved for surgical anesthesia in the 1970s, which means the medical community has more than five decades of safety data on it across age groups and in combination with other medications. Its depression-specific formulation, the nasal spray esketamine (brand name Spravato), received FDA approval in 2019, a separate and more recent approval specific to treatment-resistant depression rather than the older anesthetic indication.
Psilocybin, as practiced under Oregon’s program, uses whole dried fruit bodies, meaning the full spectrum of compounds present in the fungus rather than an isolated molecule. It has a longer duration than a typical ketamine session and produces a different subjective experience. Dr. Whinkin’s approach with clients who have access to both is to first discuss the legal pathway (she refers people who want psilocybin specifically to Oregon for licensed facilitation), then discuss which substance and duration fit the person’s health profile and goals.
Neither is safer by default. Ketamine’s longer track record is a real advantage for people prioritizing a well-documented safety profile. Psilocybin’s longer duration and distinct mechanism may suit people whose goals are more oriented toward the psychological and meaning-making work described elsewhere in this post. The right answer depends on your medication list, your health history, and what you’re hoping to get out of the experience, which is exactly the kind of individualized conversation worth having with a provider rather than deciding from general information alone.
This wasn’t a formal audience question, but it came up enough in the broader conversation that it belongs here, especially since isolation is a measured risk factor for older adults, not just an emotional one.
Dr. Whinkin runs a monthly, roughly 90-minute virtual integration circle specifically for older adults. The format centers on community and being witnessed, sometimes organized around a prompt, with space for people to share how they’re processing meaningful experiences, psychedelic or otherwise, through art, writing, photography, or simply talking. Abbie Rosner’s research supports the value of this kind of structure specifically for older adults: facilitators she’s spoken with often screen for whether someone has a support system to return to, because a spouse or family member’s reaction to a profound experience isn’t always understanding, and people need somewhere to process what came up.
The stakes here are higher than they might first appear. The U.S. Surgeon General’s 2023 advisory on loneliness and social isolation found that social isolation among older adults is associated with approximately $6.7 billion in excess Medicare spending annually, and that chronic loneliness and social isolation raise dementia risk in older adults by approximately 50%. Both figures are confirmed in the Surgeon General’s own advisory and cited consistently across subsequent research.
The film, directed by Scott Wright, is available at thenextchapterfilm.com. It features interviews with older adults about their experiences with psychedelic medicine, including Abbie Rosner (I’m also in the film talking about microdosing.). On Sunday, September 13th @4-6pmPT, there will be a live virtual screening with Scott, Abbie, and me followed by a panel discussion. I encourage you to get tickets here.
The question that surfaced repeatedly in different forms at this Salon was whether psychedelic medicine can do something at the end of life, or in the later chapters of life, that conventional medicine has not been able to do. The evidence says: possibly, for specific conditions, with appropriate clinical support, and with honest accounting of the contraindications.
If a specific question here connects to something you’re navigating, feel free to use me as a resource.
Take care,
April
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.